市場調查報告書

抗憂鬱症藥市場(2019年∼2025年)

Antidepressant Drugs Market 2019-2025

出版商 Orion Market Research Pvt Ltd 商品編碼 949428
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
抗憂鬱症藥市場(2019年∼2025年) Antidepressant Drugs Market 2019-2025
出版日期: 2020年05月21日內容資訊: 英文
簡介

全球抗憂鬱症藥市場,預計在預測期間內將大幅度成長。帶動該市場成長的主要原因,是憂鬱症的盛行率增加,老年人口增加,副作用少的新藥登場等。再加上人們之間壓力高漲,酒精消費量和抽煙數量增多引起疾病,抗憂鬱症藥的採用增加在預測期間內可能促進市場成長。但,在新興經濟圈無法取得醫藥品,認識的缺乏,可能妨礙在預測期間內該市場的成長。

本報告提供全球抗憂鬱症藥市場的相關調查,市場趨勢和機會,成長及阻礙因素,各憂鬱症性障礙、藥物類別、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的洞察和目前市場趨勢
  • 法律規章

第3章 競爭情形

  • 主要企業分析
    • 概況
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 主要策略分析

第4章 市場決策要素

  • 成長要素
  • 阻礙因素
  • 市場機會

第5章 市場區隔

  • 各憂鬱症性障礙
    • 重度憂鬱症(MDD)
    • 強迫性精神官能症(OCD)
    • 廣泛性焦慮症(GAD)
    • 恐慌症(PD)
    • 其他
  • 各類藥物
    • 選擇性血清素再回收抑制劑(SSRI)
    • 血清素-正腎上腺素再回收抑制劑(SNRI)
    • 三環抗憂鬱藥物(TCA)
    • 單胺氧化酶抑制劑(MAOI)
    • 其他藥(非典型抗憂鬱症藥)

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他
  • 其他地區

第7章 企業簡介

  • Alkermes Plc
  • Allergan PLC
  • Breckenridge Pharmaceutical, Inc.
  • AstraZeneca Plc
  • Bristol Myers Squibb Co.
  • Camber Pharmaceutical Inc.
  • Eli Lilly & Co.
  • GlaxoSmithKline Plc
  • H. Lundbeck A/S
  • Intellipharmaceutics International Inc.
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceuticals Ltd.
  • 武田藥品工業株式會社
  • Teva Pharmaceutical Industries Ltd.
目錄
Product Code: OMR2021747

Global Antidepressant Drugs Market Size, Share & Trends Analysis Report by Depressive Disorder (Major Depressive Disorder (MDD), Obsessive-compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD), Panic Disorder (PD), and Other Depressive Disorders), By Drug Class (Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants, Monoamine Oxidase Inhibitors (MAOIs), and Other Medications) Forecast, 2019-2025

The global antidepressant drug market is estimated to grow significantly during the forecast period. The primary factors that drive the growth of the market include increased prevalence of depression, rising geriatric population along with the advent of novel drugs with minimum side effects associated. Further, increasing stress levels among the peoples and elevated alcohol consumption and smoking also lead to this disorder which may encourage the adoption of antidepressant drugs and drive the market growth during the forecast period. However, lack of awareness along with the unavailability of the drugs in the undeveloped economies is expected to hamper the growth of the market during the forecast period.

The global antidepressant drugs market is segmented on the basis of depressive disorder and drug class. Based on the depressive disorder, the market is segmented intomajor depressive disorder (MDD), obsessive-compulsive disorder (OCD), generalized anxiety disorder (GAD), panic disorder (PD), and other depressive disorders. MDD is likely to hold a significant share in the market. Based on the drug class, the market is segmented as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants, monoamine oxidase inhibitors (MAOIs), and other medications. SNRIs segment is projected to hold a significant share in the market.

Geographically, the study of the global antidepressant drugs market report covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), and the Rest of the World. Asia-Pacific is estimated to exhibit a significant growth rate in the global market during the forecast period. The increasing geriatric population in the region drives the growth of the market. In addition, improving healthcare infrastructure further gives a boost to the regional growth of the market.

Moreover, the study of the global antidepressant drugs market report covers the analysis of various players operating in the market. Some of the key players covered in the report includePfizer Inc., Eli Lilly & Co., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services Inc., Merck & Co., Inc., Novartis International AG, Sanofi S.A., Bristol Myers Squibb Co., Intellipharmaceutics International Inc., and GlaxoSmithKline Plc.

Research Methodology

The market study of the global antidepressant drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary sources include:

  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog

The report is intended for pharmaceutical companies, drug manufacturers, contract manufacturers, industry associations and experts, research organizations,academic institutes, government organizations, regulatory bodies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. Global Antidepressant Drugs Market Research and Analysis by Depressive Disorder

2. Global Antidepressant Drugs Market Research and Analysis by Drug Class

The Report Covers:

  • Comprehensive research methodology of the global antidepressant drug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global antidepressant drugs market.
  • Insights about market determinants which are stimulating the global antidepressant drugs market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of the market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Antidepressant Drugs Market by Depressive Disorder
    • 5.1.1. Major Depressive Disorder (MDD)
    • 5.1.2. Obsessive-compulsive Disorder (OCD)
    • 5.1.3. Generalized Anxiety Disorder (GAD)
    • 5.1.4. Panic Disorder (PD)
    • 5.1.5. Other Depressive Disorders
  • 5.2. Global Antidepressant Drugs Market by Drug Class
    • 5.2.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
    • 5.2.2. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
    • 5.2.3. Tricyclic Antidepressants (TCA)
    • 5.2.4. Monoamine Oxidase Inhibitors (MAOIs)
    • 5.2.5. Other Medications (Atypical Antidepressants)

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Alkermes Plc
  • 7.2. Allergan PLC
  • 7.3. Breckenridge Pharmaceutical, Inc.
  • 7.4. AstraZeneca Plc
  • 7.5. Bristol Myers Squibb Co.
  • 7.6. Camber Pharmaceutical Inc.
  • 7.7. Eli Lilly & Co.
  • 7.8. GlaxoSmithKline Plc
  • 7.9. H. Lundbeck A/S
  • 7.10. Intellipharmaceutics International Inc.
  • 7.11. Johnson & Johnson Services Inc.
  • 7.12. Merck & Co., Inc.
  • 7.13. Mylan N.V.
  • 7.14. Novartis International AG
  • 7.15. Pfizer Inc.
  • 7.16. Sanofi S.A.
  • 7.17. Sun Pharmaceuticals Ltd.
  • 7.18. Takeda Pharmaceutical Co.
  • 7.19. Teva Pharmaceutical Industries Ltd.

LIST OF TABLES

  • 1. GLOBAL ANTIDEPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY DEPRESSIVE DISORDERS, 2018-2025 ($ MILLION)
  • 2. GLOBAL MAJOR DEPRESSIVE DISORDER (MDD) DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 3. GLOBAL OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 4. GLOBAL GENERALIZED ANXIETY DISORDER (GAD) DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 5. GLOBAL PANIC DISORDER (PD) DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 6. GLOBAL OTHER DEPRESSIVE DISORDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 7. GLOBAL ANTIDEPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
  • 8. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 9. GLOBAL SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 10. GLOBAL TRICYCLIC ANTIDEPRESSANTS (TCA) MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 11. GLOBAL MONOAMINE OXIDASE INHIBITORS (MAOIs) MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 12. GLOBAL OTHER ANTIDEPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 13. GLOBAL ANTIDEPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
  • 14. NORTH AMERICAN ANTIDEPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 15. NORTH AMERICAN ANTIDEPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY DEPRESSIVE DISORDERS, 2018-2025 ($ MILLION)
  • 16. NORTH AMERICAN ANTIDEPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
  • 17. EUROPEAN ANTIDEPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 18. EUROPEAN ANTIDEPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY DEPRESSIVE DISORDERS, 2018-2025 ($ MILLION)
  • 19. EUROPEAN ANTIDEPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
  • 20. ASIA-PACIFIC ANTIDEPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 21. ASIA-PACIFIC ANTIDEPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY DEPRESSIVE DISORDERS, 2018-2025 ($ MILLION)
  • 22. ASIA-PACIFIC ANTIDEPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
  • 23. REST OF THE WORLD ANTIDEPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY DEPRESSIVE DISORDERS, 2018-2025 ($ MILLION)
  • 24. REST OF THE WORLD ANTIDEPRESSANT DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ANTIDEPRESSANT DRUGS MARKET SHARE BY DEPRESSIVE DISORDERS, 2018 VS 2025 (%)
  • 2. GLOBAL ANTIDEPRESSANT DRUGS MARKET SHARE BY DRUG CLASS, 2018 VS 2025 (%)
  • 3. GLOBAL ANTIDEPRESSANT DRUGS MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
  • 4. US ANTIDEPRESSANT DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 5. CANADA ANTIDEPRESSANT DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 6. UK ANTIDEPRESSANT DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. FRANCE ANTIDEPRESSANT DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. GERMANY ANTIDEPRESSANT DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. ITALY ANTIDEPRESSANT DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. SPAIN ANTIDEPRESSANT DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 11. ROE ANTIDEPRESSANT DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 12. INDIA ANTIDEPRESSANT DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 13. CHINA ANTIDEPRESSANT DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 14. JAPAN ANTIDEPRESSANT DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC ANTIDEPRESSANT DRUGS MARKET SIZE, 2018-2025 ($ MILLION)
  • 16. REST OF THE WORLD ANTIDEPRESSANT DRUGS MARKET SIZE, 2018-2025 ($ MILLION)